F2RL3 and COVID-19: To reinforce the importance of PAR-4 as a mediator of IL-6 release, recently PARs have been indicated as a possible target to treat pro-inflammatory cytokine and prothrombotic harmful effects, in COVID-19 [57], and in other pro-thrombotic conditions, as suggested in a recent Consensus Document on Atherothrombosis and Thromboembolism [58].